← Back to Feed CACHED · 2026-08-04 17:19:50 · CACHE_KEY CVE-2026-17583
CVE-2026-17583 · CWE-354 · Disclosed 2026-07-31

Thermo Fisher Applied Biosystems HID Software Missing Integrity Verification on .fsa/.hid DNA Data Files

ASSESSED — NOISGATE V0.5
Vendor
Reassessed
Verdict:
Do you agree?
01 · The Real Story

Someone left the evidence locker unlocked for 30 years, and the lock they just added only works on newer doors

CVE-2026-17583 is a missing-integrity-verification flaw in Thermo Fisher Scientific's Applied Biosystems Human Identification software — the instruments and analysis tools that produce .fsa and .hid DNA data files for forensic crime labs, paternity testing, and clinical genetics. Because these file formats never included digital signatures or checksums, an attacker with access to the laboratory file server can modify DNA analysis output files before they're loaded into interpretation software like GeneMapper ID-X, and the software will accept the tampered data without any warning. Researchers demonstrated combining two DNA profiles into a single file that appeared unmodified since 2015. Affected Data Collection Software versions include 3500/3500xL ≤4.0.2, 3730/3730xL ≤5.0.2, SeqStudio ≤1.2.5, SeqStudio Flex ≤1.2.0, and GeneMapper ID-X ≤1.7.3. Three end-of-life product lines (3130, ABI PRISM 3100/3100-Avant, ABI PRISM 310) will receive no patch.

The vendor-assigned CVSS v4.0 score of 8.2 (High) reflects the seriousness of undetectable evidence tampering, and that's fair *within the forensic-lab domain*. But for a general enterprise security team managing 10,000 Windows/Linux hosts, this score dramatically overstates urgency. The affected software runs on a tiny population of purpose-built genetic analyzer workstations in accredited laboratories — not on domain controllers, application servers, or user endpoints. The attack requires authenticated access to lab file storage and specialized knowledge of DNA analysis workflows. There is no code execution, no lateral movement, and no privilege escalation. The 8.2 is a domain-specific integrity score, not an enterprise-IT risk score.

"Lab-only data-integrity flaw; most enterprises have zero instances to patch."
02 · The Attack Path

3 steps from start to impact.

STEP 01

Gain access to lab file storage

The attacker must obtain local or remote authenticated access to the file server or shared storage where the genetic analyzer instruments write .fsa and .hid output files. This could be via stolen credentials, insider access, or exploitation of a separate vulnerability on the lab network. The storage is typically a Windows share or local disk on the instrument controller PC.
Conditions required:
  • Authenticated access to lab file server or instrument workstation
  • Knowledge that the target organization operates Applied Biosystems genetic analyzers
Where this breaks in practice:
  • Lab networks are typically segmented from corporate IT, often air-gapped in accredited forensic facilities
  • Physical access controls (badge, biometric) are standard in forensic and clinical labs
  • Chain-of-custody procedures create audit trails outside the digital system
Detection/coverage: No automated scanner or EDR signature will detect this access pattern as it uses legitimate file-system operations with valid credentials.
STEP 02

Identify and modify target .fsa/.hid files

The attacker locates the DNA data output files on disk and modifies them using a hex editor or purpose-built tool. Because the file format lacks any integrity verification (no signatures, no checksums, no MACs), arbitrary modifications to electropherogram data, sample metadata, or allele calls are accepted silently. The attacker needs to understand the binary file format and DNA analysis concepts to make plausible modifications.
Conditions required:
  • Understanding of .fsa/.hid binary file format structure
  • Knowledge of DNA electropherogram data to craft plausible modifications
Where this breaks in practice:
  • Requires specialized forensic genetics knowledge — this is not a script-kiddie attack
  • File modification timestamps may be monitored by lab LIMS (Laboratory Information Management System)
  • Some labs use write-once media or WORM storage for instrument output
Detection/coverage: File integrity monitoring (FIM) tools like OSSEC or Tripwire on the lab server would detect file modifications, but most labs do not deploy enterprise FIM on instrument storage.
STEP 03

Tampered data accepted by analysis software

When a forensic analyst loads the modified files into GeneMapper ID-X or equivalent analysis software, the application processes them without any integrity check. The tampered DNA profiles appear identical to legitimate data. The analyst has no technical mechanism within the software to distinguish authentic from modified files.
Conditions required:
  • Analyst must load the tampered files before any external integrity check is performed
Where this breaks in practice:
  • Accredited labs follow ISO 17025 / FBI QAS standards that include procedural controls beyond software
  • Dual-analyst review is standard practice in forensic casework, though it cannot detect file-level tampering
  • Re-running the sample on the instrument would produce different results, potentially raising suspicion
Detection/coverage: The patched versions (4.0.3, 5.0.3, 1.2.6, 1.2.1, 1.7.4) add digital signatures that detect post-creation modification. No pre-patch detection mechanism exists within the software.
03 · Intelligence Metadata

The supporting signals.

In-the-Wild ExploitationNone reported. Thermo Fisher told the Wall Street Journal it knows of no instances of exploitation. No campaigns or threat actor associations identified.
Proof of ConceptControlled research demonstration only — researchers Nathan Adams, Kevin Dyer, and Laura Gaydosh Combs demonstrated combining two DNA profiles into a single file appearing unaltered. No public weaponized PoC or exploit code.
EPSS ScoreNot yet scored by FIRST (CVE is days old as of 2026-08-05). Expected to be very low given the niche attack surface.
KEV StatusNot listed in CISA Known Exploited Vulnerabilities catalog.
CVSS v4.0 (Vendor)8.2 / High — assigned by Thermo Fisher as CNA. No CVSS v3.1 vector published. No NVD score yet.
Affected Versions3500/3500xL DCS ≤4.0.2, 3730/3730xL DCS ≤5.0.2, SeqStudio GA DCS ≤1.2.5, SeqStudio Flex ≤1.2.0, GeneMapper ID-X ≤1.7.3. EOL (no patch): 3130, ABI PRISM 3100/3100-Avant, ABI PRISM 310.
Fixed Versions3500/3500xL DCS 4.0.3, 3730/3730xL DCS 5.0.3, SeqStudio GA DCS 1.2.6, SeqStudio Flex 1.2.1, GeneMapper ID-X 1.7.4. Patches add digital signatures to output files.
Scanning/Exposure DataNo Shodan/Censys/GreyNoise exposure — these are offline laboratory instruments, not internet-facing services. Installed base is limited to forensic, clinical, and research genetics laboratories.
Disclosure Date2026-07-31 (vendor bulletin date); public coverage began 2026-08-03.
ResearchersNathan Adams, Kevin Dyer, and Laura Gaydosh Combs, coordinated with CISA.
04 · The Call

noisgate verdict.

Final Verdict
DOWNGRADED to MEDIUM (5.5/10)

The single most decisive factor is the extremely narrow installed base — Applied Biosystems genetic analyzers exist only in forensic, clinical, and research laboratories, representing effectively 0% of a typical enterprise's 10,000-host fleet. No code execution, lateral movement, or privilege escalation is possible; the impact is limited to data integrity of DNA evidence files on isolated lab workstations.

HIGH Vulnerability mechanics and affected product scope
HIGH No in-the-wild exploitation
MEDIUM Installed base estimates (no public deployment census)
LOW EPSS and long-term threat actor interest

Why this verdict

  • Negligible enterprise footprint: Applied Biosystems genetic analyzers are specialized laboratory instruments. A typical enterprise IT environment has zero instances. Even hospital systems have these only in dedicated genetics departments on segmented lab networks.
  • Authenticated local/network access required: The attacker must already have valid credentials to the lab file server or physical access to the instrument workstation — this is a post-compromise prerequisite that assumes prior breach of a segmented lab environment.
  • No code execution or propagation: This is a pure data-integrity flaw. There is no RCE, no privilege escalation, no lateral movement capability. The blast radius is confined to the integrity of .fsa/.hid files on a single lab system.
  • Role multiplier: The affected component is a laboratory instrument controller — it does not appear in any high-value enterprise role (not a DC, hypervisor, CI/CD, backup, network edge, IdP, or kernel-mode agent). The blast radius is *evidence integrity* within a single lab workflow, not fleet compromise. For the <0.1% of enterprises that are forensic labs, the integrity impact is severe but still bounded to the lab data tier.
  • Procedural controls exist independently: Accredited forensic labs operate under ISO 17025 and FBI QAS standards with chain-of-custody controls, dual-analyst review, and physical access restrictions that provide defense-in-depth beyond the software layer.

Why not higher?

Upgrading to HIGH would require either a broader installed base, code execution capability, or evidence of active exploitation — none of which exist. The affected systems are offline laboratory instruments with no internet exposure, the attack requires authenticated access plus specialized genetics knowledge, and the impact cannot cascade beyond the lab's data files. No threat actor has demonstrated interest.

Why not lower?

Downgrading to LOW or IGNORE would understate the risk for organizations that *do* operate forensic genetics labs, where undetected evidence tampering could undermine criminal prosecutions or clinical diagnoses. The 30-year window of unprotected files and three EOL product lines with no patch available mean some organizations face a real remediation gap. The CISA coordination also signals legitimate concern.

05 · Compensating Control

What to do — in priority order.

  1. Deploy file integrity monitoring on lab instrument output directories — Configure FIM (Tripwire, OSSEC, Wazuh, or similar) on all directories where genetic analyzers write .fsa and .hid files. Alert on any modification after initial file creation. This is your primary compensating control and should be deployed within the noisgate remediation window of 365 days for MEDIUM findings.
  2. Enable write-once storage for instrument output — Configure instrument output directories to use WORM (Write Once Read Many) storage or immutable file flags. On Windows, use NTFS permissions to grant the instrument service account write-only and analysts read-only access. This prevents post-creation tampering regardless of patch status.
  3. Segment lab networks from corporate IT — If not already segmented, place genetic analyzer workstations and their file storage on a dedicated VLAN with no inbound access from the corporate network. This is standard for accredited labs but verify the control is in place.
  4. Patch supported products to signature-enabled versions — Update to 3500/3500xL DCS 4.0.3, 3730/3730xL DCS 5.0.3, SeqStudio GA DCS 1.2.6, SeqStudio Flex 1.2.1, and GeneMapper ID-X 1.7.4. These versions add digital signatures to output files. Coordinate patching with lab operations to avoid disrupting active casework.
  5. Plan EOL instrument replacement — The 3130, ABI PRISM 3100/3100-Avant, and ABI PRISM 310 will receive no patch. Begin procurement planning for replacement instruments. Until replaced, these must rely entirely on FIM and procedural controls.
What doesn't work
  • EDR/antivirus — this is not malware execution; the attacker modifies data files using legitimate file operations. No EDR signature will detect hex-editing a .fsa file.
  • Network IDS/IPS — the file modification happens on local or SMB-attached storage using normal file I/O. There is no network exploit signature to detect.
  • WAF or perimeter controls — these instruments are not web-facing. Perimeter defenses are irrelevant to the attack path.
  • Patching alone for EOL instruments — three product lines will never receive a fix. Compensating controls are the only option for these.
06 · Verification

Crowdsourced verification payload.

Run this script on each Applied Biosystems instrument workstation or file server as a local administrator. It checks installed software versions against the patched baselines. Example: .\Check-CVE-2026-17583.ps1

noisgate-verify.ps1
POWERSHELLREAD-ONLYSAFE
#Requires -Version 5.1
<#
  Check-CVE-2026-17583.ps1
  Checks for Thermo Fisher Applied Biosystems software affected by CVE-2026-17583.
  Run on instrument workstations as local admin.
  Exit codes: 1 = VULNERABLE, 0 = PATCHED, 2 = UNKNOWN
#>

$ErrorActionPreference = 'SilentlyContinue'
$found = $false
$vulnerable = $false

# Define affected products and their fixed versions
$products = @(
    @{ Pattern = '3500.*Data Collection'; FixedMajor = 4; FixedMinor = 0; FixedBuild = 3; Name = '3500/3500xL DCS' },
    @{ Pattern = '3730.*Data Collection'; FixedMajor = 5; FixedMinor = 0; FixedBuild = 3; Name = '3730/3730xL DCS' },
    @{ Pattern = 'SeqStudio.*Genetic.*Data Collection'; FixedMajor = 1; FixedMinor = 2; FixedBuild = 6; Name = 'SeqStudio GA DCS' },
    @{ Pattern = 'SeqStudio.*Flex'; FixedMajor = 1; FixedMinor = 2; FixedBuild = 1; Name = 'SeqStudio Flex' },
    @{ Pattern = 'GeneMapper.*ID-X'; FixedMajor = 1; FixedMinor = 7; FixedBuild = 4; Name = 'GeneMapper ID-X' }
)

# EOL products (always vulnerable, no patch)
$eolPatterns = @('3130', 'ABI PRISM 3100', 'ABI PRISM 310')

$regPaths = @(
    'HKLM:\SOFTWARE\Microsoft\Windows\CurrentVersion\Uninstall\*',
    'HKLM:\SOFTWARE\WOW6432Node\Microsoft\Windows\CurrentVersion\Uninstall\*'
)

$installed = Get-ItemProperty $regPaths 2>$null | Where-Object { $_.DisplayName -match 'Applied Biosystems|Thermo Fisher|GeneMapper|SeqStudio|3500|3730|3130|ABI PRISM' }

foreach ($app in $installed) {
    # Check EOL products
    foreach ($eol in $eolPatterns) {
        if ($app.DisplayName -match $eol) {
            Write-Host "[VULNERABLE] EOL product found: $($app.DisplayName) - NO PATCH AVAILABLE" -ForegroundColor Red
            $found = $true
            $vulnerable = $true
        }
    }
    # Check patchable products
    foreach ($prod in $products) {
        if ($app.DisplayName -match $prod.Pattern) {
            $found = $true
            try {
                $ver = [version]$app.DisplayVersion
                $fixed = [version]("$($prod.FixedMajor).$($prod.FixedMinor).$($prod.FixedBuild)")
                if ($ver -lt $fixed) {
                    Write-Host "[VULNERABLE] $($prod.Name) v$($app.DisplayVersion) < $fixed" -ForegroundColor Red
                    $vulnerable = $true
                } else {
                    Write-Host "[PATCHED] $($prod.Name) v$($app.DisplayVersion) >= $fixed" -ForegroundColor Green
                }
            } catch {
                Write-Host "[UNKNOWN] $($prod.Name) - could not parse version: $($app.DisplayVersion)" -ForegroundColor Yellow
            }
        }
    }
}

if (-not $found) {
    Write-Host "[UNKNOWN] No Applied Biosystems / Thermo Fisher HID software detected on this host." -ForegroundColor Yellow
    exit 2
}
if ($vulnerable) {
    Write-Host "`nResult: VULNERABLE" -ForegroundColor Red
    exit 1
} else {
    Write-Host "`nResult: PATCHED" -ForegroundColor Green
    exit 0
}
07 · Bottom Line

If you remember one thing.

TL;DR
Unless you operate a forensic genetics lab, clinical sequencing facility, or research genomics department, you almost certainly have zero instances of Applied Biosystems software in your fleet — confirm this with a software inventory query and move on. If you do have these instruments, there is no noisgate mitigation SLA for MEDIUM findings — go straight to the 365-day noisgate remediation SLA by patching the five supported product lines to their signature-enabled versions (DCS 4.0.3 / 5.0.3, SeqStudio 1.2.6 / Flex 1.2.1, GeneMapper ID-X 1.7.4). Coordinate patching with lab operations to avoid disrupting active casework. In parallel, deploy file integrity monitoring on instrument output directories as a compensating control and begin replacement planning for the three EOL product lines (3130, ABI PRISM 3100, ABI PRISM 310) that will never receive a fix. If your organization handles forensic evidence subject to legal proceedings, brief your legal and quality assurance teams on the 30-year window of unprotected files — this is a chain-of-custody disclosure issue, not just a patching ticket.

Sources

  1. The Hacker News — Thermo Fisher Patches Flaw
  2. Thermo Fisher Security Bulletin (PDF)
  3. Tenable CVE Entry
  4. Rescana Advisory
  5. CybersecurityNews Coverage
  6. GBHackers Coverage
  7. Daily Security Review
Peer Review

What defenders are saying.

Submit a review attribution: handle + country only
0 flags selected · stored anonymously
Validation Results

Crowdsourced verification outputs.

Results submitted by users who ran the verification payload against their environment.